Technology | October 22, 2009

FlowCardia Expands Options for Patients With Chronic Total Occlusions


October 22, 2009 – FlowCardia Inc. yesterday began its U.S. launch of the over the wire (OTW) delivery platform for the CROSSER 14S and CROSSER 14P peripheral chronic total occlusions (CTOs) recanalization catheters. The Over the Wire CROSSER Catheter delivery platform provides interventional cardiologists, vascular surgeons, and interventional radiologists with an endovascular tool to treat even the most distal and complex peripheral occlusions. CROSSER OTW catheters facilitate guide wire exchanges using peripheral interventionalists' preferred delivery platform, thus providing various levels of catheter support, pushability, and steerability during percutaneous treatment in patients suffering from blocked arteries in the legs. "The new Over the Wire CROSSER Catheter allows me to freely exchange my guide wire, giving me the steerability and support necessary to tackle the toughest of CTOs with ease," said David Allie, M.D., a cardiothoracic surgeon at the Medical Center of Acadiana in Lafayette, La. "When faced with CTOs, I use CROSSER as my frontline therapy to stay in the central lumen, giving me the freedom to choose the best subsequent treatment option for patients suffering from completely blocked arteries." The CROSSER Catheter is a minimally-invasive endovascular device that utilizes high-frequency, mechanical vibration to facilitate passage through blockages in the peripheral and coronary arteries. It is designed as a frontline therapy to enable central lumen crossing of chronically occluded arteries thereby maximizing physicians' therapeutic options. More than 7,500 CROSSER Catheter procedures have been performed to date by physicians around the world. For more information: www.flowcardia.com


Related Content

News | Cath Lab

May 13, 2026 — According to a recently released report, the global cath lab services market was valued at $46.0 billion ...

Home May 13, 2026
Home
News | Cath Lab

April 16, 2026 — A national study led by investigators from Cedars-Sinai Health Sciences University found that ...

Home April 20, 2026
Home
News | Cath Lab

April 6, 2026 —Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its Synchrony system ...

Home April 07, 2026
Home
News | Cath Lab

March 31, 2026 — Solo Pace Inc. has announced the commercial release of the SoloPace Fusion Temporary Pacing System. The ...

Home April 03, 2026
Home
News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
Subscribe Now